Abstract Number: 014 • 2023 Pediatric Rheumatology Symposium
Characterizing Lupus in African American Children in Southern United States
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…Abstract Number: 0116 • ACR Convergence 2022
Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
Background/Purpose: Medication adherence is critical for SLE management and can be influenced by patients' barriers and beliefs about treatment. Patients of color with SLE have…Abstract Number: 0329 • ACR Convergence 2022
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…Abstract Number: 0369 • ACR Convergence 2022
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Background/Purpose: Fatigue is among the most prevalent symptoms of systemic lupus erythematosus (SLE) and is associated with patient distress, work dysfunction, and worse overall health…Abstract Number: 0634 • ACR Convergence 2022
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Background/Purpose: Kidney biopsy is a gold standard for diagnosis and prognostication of lupus nephritis (LN). While interstitial fibrosis and tubular atrophy (IFTA) predict progression to…Abstract Number: 0654 • ACR Convergence 2022
Lymphatic Dysfunction and Immune Activation in Lupus
Background/Purpose: Systemic lupus erythematosus is a prototypic autoimmune disease in which patients frequently have photosensitivity. Exposure to ultraviolet radiation (UVR) causes the eruption of cutaneous…Abstract Number: 0696 • ACR Convergence 2022
The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database
Background/Purpose: SLE is an autoimmune rheumatic disease that contributes to increased morbidity and mortality due to multi-organ involvement, infections, and accelerated atherosclerosis leading to cardiovascular…Abstract Number: 0958 • ACR Convergence 2022
Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
Background/Purpose: Despite the wide use of AZA during pregnancy, there are no studies evaluating the impact of pregnancy on AZA metabolites 6-thioguanine nucleotide (6-TGN) and…Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…Abstract Number: 0996 • ACR Convergence 2022
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
Background/Purpose: Proposed targets of SLE treatment include lupus low disease activity state (LLDAS), clinical remission and complete remission. Whether treatment can be tapered after achieving…
- « Previous Page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- …
- 181
- Next Page »
